Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
Launched by NEOTHETICS, INC · Mar 24, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy male or non-pregnant female subjects
- • Capable of providing written consent.
- • BMI \< 30 kg/m2
- • Stable diet and exercise routine
- • Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat
- Exclusion Criteria:
- • Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
- • Plan on starting a weight loss or exercise program during the study.
- • Known hypersensitivity to study drugs
About Neothetics, Inc
Neothetics, Inc. is a clinical-stage biotechnology company focused on developing innovative aesthetic treatments aimed at addressing unmet needs in the field of dermatology and cosmetic medicine. With a commitment to advancing the science of body contouring and skin health, Neothetics leverages cutting-edge research and technology to create safe and effective solutions. The company is dedicated to enhancing patient outcomes and quality of life through rigorous clinical trials and a robust pipeline of transformative therapies, positioning itself as a leader in the aesthetics industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Coral Gables, Florida, United States
Clearwater, Florida, United States
Miami, Florida, United States
Fridley, Minnesota, United States
Hot Springs, Arkansas, United States
Norfolk, Virginia, United States
Plano, Texas, United States
Omaha, Nebraska, United States
Warren, Michigan, United States
Arlington Heights, Illinois, United States
Boca Raton, Florida, United States
Charlotte, North Carolina, United States
Buffalo Grove, Illinois, United States
Beverly Hills, California, United States
Louisville, Kentucky, United States
Santa Monica, California, United States
Fremont, California, United States
College Station, Texas, United States
Salt Lake City, Utah, United States
San Diego, California, United States
New York, New York, United States
Aventura, Florida, United States
Katy, Texas, United States
Tucson, Arizona, United States
San Diego, California, United States
Hackensack, New Jersey, United States
New York, New York, United States
Smithtown, New York, United States
Chapel Hill, North Carolina, United States
Austin, Texas, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Maria Feldman
Study Director
Neothetics, Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials